Other languages Senhwa Biosciences, Inc.

Equities

6492

TW0006492002

End-of-day quote Taipei Exchange Other stock markets 18:00:00 2024-05-16 EDT			5-day change	1st Jan Change
42.45 ^TWD	+1.80%		+3.28%	-16.60%

03-20	Senhwa Biosciences Announces First Patient Dosed in the Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection in Taiwan	CI
03-14	Senhwa Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Senhwa Biosciences Announces First Patient Dosed in the Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection in Taiwan	03-20
Senhwa Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-14
Senhwa Biosciences, Inc. Decides to Early Terminate the Phase II study of Silmitasertib to treat hospitalized patients with COVID-19	01-05
Senhwa Biosciences Receives Taiwan FDA IND Approval for Phase Ii Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection	12-26
Senhwa Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09
Senhwa Biosciences, Inc. Announces First Patient Successfully Dosed in Taiwan Phase II Study of Silmitasertib in Hospitalized Adults with COVID-19	11-09
Senhwa Biosciences Announces Investigational New Drug Submission to U.S. Food and Drug Administration for Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection	23-10-19
Senhwa Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09
Senhwa Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-22
Senhwa Biosciences Receives Taiwan Fda Ind Approval for Phase II Study of Silmitasertib in Patients with Moderate to Severe Covid-19	23-04-28
Senhwa Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30
Senhwa Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-11
Senhwa Biosciences, Inc. Announces First Patient Successfully Dosed in Phase I Study of Pindnarulex in Combination with Pfizer's Talazoparib for the Treatment of Prostate Cancer	22-10-31
Senhwa Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11
Senhwa Biosciences, Inc. Pindnarulex in Combination Study with Pfizer's Talazoparib for the Treatment of Prostate Cancer Granted Approval to Initiate from Australian HREC	22-06-06
Senhwa Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-11
Senhwa Biosciences, Inc. Presents Positive Initial Data from Phase 1 Clinical Trial of Silmitasertib Used to Treat Patients with Advanced Basal Cell Carcinoma at 2022 AAD Annual Meeting	22-03-28
Senhwa Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-11
Senhwa Biosciences, Inc. Receives US FDA Fast Track Designation for the Treatment of Solid Tumors with BRCA1/2, PALB2 and Other HR Gene Mutations	22-01-25
Senhwa Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Senhwa Biosciences, Inc.

Equities

6492

TW0006492002

Other languages

Filters